Before You Take Your Next Statin, Watch THIS (New Research)

Scientific concepts, discoveries, and nature/biological phenomena

Statins and metabolic/hormonal effects (2024 research)

• Statins (e.g., atorvastatin) reduce cholesterol effectively.
• In a Cell Metabolism (2024) study of new statin users:
  • Total cholesterol and LDL decreased quickly (within ~1 week).
  • Blood sugar worsened over time:
    • HbA1c (average blood glucose over ~3 months) increased by about 0.06% on average.
    • Insulin resistance increased (insulin rose and the body needed more insulin).
  • GLP-1 decreased significantly (down to roughly half by later measurements).
  • The drug-related hormonal change was linked to gut microbial changes rather than the liver directly causing it.

Role of gut bacteria and bile acids (mechanistic findings)

• Statins were proposed to alter the gut microbiome, specifically suppressing bacteria involved in bile acid conversion.
• Key bile-acid pathway:
  • Liver produces bile acids
  • Intestinal bacteria convert them into UDCA
  • UDCA is associated with GLP-1 production
• Proposed chain of effects:
  • Statins suppress gut bacteria (notably the “Clostridium” group)
  • → Less conversion to UDCA
  • → Lower UDCA
  • → Lower GLP-1
  • → Higher insulin resistance / higher blood sugar

Evidence from animal/transplant experiments (as described):

• Mice given statins developed similar issues (lower GLP-1, worse glucose control).
• When mice gut microbiota were destroyed with antibiotics, statins no longer caused the glucose/GLP-1 changes.
• Fecal microbiota transfer:
  • Transplanting feces from long-term statin users into normal mice led to insulin resistance.
• Rescue interventions:
  • Restoring missing bacteria rescued the phenotype.
  • Giving UDCA directly also rescued the phenotype.

Diet interaction mentioned:

• In mice on a high-fiber diet, the statin-related glucose problem was not observed (fiber supports similar bacteria that statins suppress).
• This was presented as mouse evidence only, not proven in humans in the same way.

GLP-1 biology and connection to diabetes/weight loss drugs

• GLP-1 is described as a hormone produced by intestinal cells after food enters the gut.
• Reported functions:
  • Stimulates insulin secretion when blood sugar is high
  • Slows stomach emptying
  • Helps signal satiety to the brain
• The video links GLP-1 biology to modern therapeutics (e.g., Ozempic).

Historical discovery behind GLP-1–mimicking drugs

• John Eng (and colleagues) studied lizard venom and isolated exendin-4, described as GLP-1–like.
• Exendin-4 is described as more stable than human GLP-1, producing a longer-lasting effect—enabling development of GLP-1-based medications.

UDCA (ursodeoxycholic acid) and bear bile history and drug rationale

• The video traces UDCA history from traditional use to modern pharmacology:
  • Traditional Chinese medicine used dried bear bile
  • Tang Dynasty (~659) early descriptions (as stated)
  • 1902: Olof Hammarsten extracted a substance from polar bear gall bladders; named it after the animal due to limited chemistry
  • 1927: Masato Shoda isolated the same substance from black bear bile and named it ursodeoxycholic acid (UDCA)
  • 1936: structure elucidated; lab production became possible
  • Modern prescription form in the US: ursodiol

Small clinical hint described (as stated):

• 5 patients on statins >6 months with slightly elevated A1C
• Added UDCA 500 mg/day for 2 months, while continuing statins
• Reported outcomes (as stated):
  • A1C down
  • Insulin down
  • Insulin resistance down
  • Liver enzymes remained normal
  • Lipids preserved: LDL unchanged, HDL improved
• Limitations emphasized:
  • No control group
  • Not double-blind
  • Very small sample size

Larger randomized trial mentioned:

• A “proper” trial was said to be underway:
  • Randomized, placebo-controlled, 6 months, adults 40–75

Large-scale evidence on diabetes risk (Oxford analysis)

• May 2024: Oxford published a large meta-analysis of statins and blood sugar:
  • 123,000 participants
  • 19 trials
  • Double-blind style: neither patients nor doctors knew allocation
  • Follow-up >4 years
• Reported effect sizes:
  • A1C increased about 0.06% at standard dose
  • Up to about 0.08% at the highest dose
• Interpretation given:
  • Many new diabetes diagnoses occurred in people already near the threshold
  • Net cardiovascular benefit remained substantial because statins also prevent heart attacks and strokes
• Benefit/risk numbers provided (as stated):
  • About 1 additional diabetes case per 1,000 people per year
  • About 5 heart attacks or strokes prevented per 1,000 people per year

Guideline context (US statin eligibility expansion)

• The video claims new cholesterol guidelines expanded statin risk eligibility:
  • Age range expanded from 40–75 to 30–79
• Reported impact estimate (as stated):
  • 87.5 million US adults meet criteria
  • 21.5 million previously uninsured
  • Higher proportions in older age groups (e.g., ~85% at 60, 93% at 70; as stated)

---

Methodology / study designs outlined (as described in the subtitles)

• Cell Metabolism (2024) statin initiation study

  • Participants:
    • 30 patients starting atorvastatin 20 mg
    • 10 comparator patients with similar cholesterol problems choosing not to take statins
  • Duration: 16 weeks
  • Blood tests at: baseline, 1 week, 4 weeks, 16 weeks
  • Outcomes: cholesterol, HbA1c, insulin/insulin resistance, GLP-1, plus stool/bile acid analyses (mechanistic part described later)
  • Bacteria implicated via stool/bile acid changes

• Animal mechanistic experiments (described)

  • Statins given to mice → phenotype reproduced
  • Antibiotics used to disrupt gut microbiota → statin effect disappears
  • Fecal transplant from long-term statin users → insulin resistance in recipient mice
  • Rescue:
    • restore bacteria or
    • administer UDCA directly

• Bear bile / UDCA clinical rationale (described small pilot)

  • 5 statin-treated patients with elevated A1C
  • Added UDCA 500 mg/day for 2 months
  • No control group; results treated as a hint

• Planned human trial (described)

  • Randomized, placebo-controlled, 6 months
  • Adults 40–75

• Oxford large-scale analysis (May 2024, described)

  • 123,000 participants across 19 trials
  • Monitoring >4 years
  • Quantified A1C change and cardiovascular outcomes

---

Researchers and sources featured (named in the subtitles)

People (researchers/historical figures)

• Neil K. Shah (video host; described as Johns Hopkins/NIH-funded researcher in nursing; CEO of Cariaia)
• Akira Endo (inventor/tester of the statin concept; worked at a pharmaceutical company in Tokyo; died June 2024)
• John Eng (identified exendin-4 from lizard venom)
• Olof Hammarsten (1902 extraction of bile substance; polar bear gall bladders)
• Masato Shoda (1927 isolated substance from black bear bile; named ursodeoxycholic acid)

Institutions / journals / organizations / studies (named)

• Cell Metabolism (journal for the described 2024 statin initiation study)
• Oxford (Oxford group for the May 2024 large analysis)
• Johns Hopkins University
• NIH (National Institutes of Health)
• American Heart Association
• American College of Cardiology
• 10 other organizations (unnamed)
• VA (Veterans Affairs Administration) (context for Eng’s work)

(No additional author names for the Cell Metabolism or Oxford studies were provided in the subtitles.)